Top-line clinical results from US study with lead candidate IdeS to be presented at the American Transplant Congress
(WorldNews Sweden)

Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company developing novel immunomodulatory enzymes, today announced that top-line clinical results from the ongoing investigator initiated US study will be presented in an oral session at the 2017 American Transplant Congress (ATC) in Chicago, U.S. on 30 April. The top-line results from the study, demonstrate that treatment with IdeS completely eliminates donor specific antibodies (DSAs) and enables transplantation of HLA incompatible patients. An abstract with the top-line data and conclusions is available through the ATC website http://atcmeeting.org The abstract, titled "Experience with The Bacterial Enzyme IdeS (IgG...